Inactive Instrument

News Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
05-28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	06-12	AQ
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	06-11	AQ
European Biosimilar Regulatory Update	06-10	AQ
Corporate Presentation: June 2024	06-05	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	05-29	AQ
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	05-28	MT
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	05-28	AQ
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	05-28	CI
CoStar Group has room for expansion	05-21
Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024	05-16
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	05-15	AQ
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	05-13	MT
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	05-13	AQ
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	05-13	CI
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	05-09	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	05-02	AQ
Outlook Therapeutics, Inc. Announces Change in Headquarters Address	05-01	CI
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	04-29	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	04-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncobiologics Inc Nasdaq

Equities

US68235M2044

Summary

Filters